The cosmetic industry is booming in the current decade and has experienced over projected three-fold increase in the turnover in the last few decades. There has been a rise in total number of the non-surgical therapies, including injections of dermal fillers and wrinkle relaxers. The trend is primarily due to various technological advancements, such as less risk of infections, low recovery time, no blood loss, and overall reduction in the procedural costs. Thus, the rise in the number of these procedures has encouraged the growth of overall industry including facial injectable.
Additionally, factors like, rising awareness about the external appearance among old and young individuals and growing awareness regarding availability of numerous products and procedures, accredited to the social media influence and increasing globalization are likely to further fuel the growth of the market. Segment Overview
On the basis of type, the facial injectable market is segmented into collagen, botulinum toxin type A, calcium hydroxylapatite, hyaluronic acid, and polymer fillers. The hyaluronic acid segment ruled the market in 2019 and is anticipated to witness productive growth during the forecast period. Increasing use of hyaluronic acid in the cosmetic industry is likely to support the market growth. Hyaluronic acid has become an essential part of the cosmetics owing to strong water holding properties and minor allergic reactions. Cosmetic-grade products has a low molecular weight which facilitates deep penetration of product in the epidermis, releases antioxidants, helps retain water in the cells, and delays aging process, hence contributing towards the market demand.Regional Overview
North America held major market share in 2019, owing to the increased spending on various aesthetic procedures and easy accessibility of the products. In addition, existence of large geriatric population base in the U.S. and Canada is further likely to fuel demand for these injectables during the forecast period. As per the estimates provided by United States Census Bureau (USCB) in 2014, the geriatric population in the country is likely to reach 83.7 million by the year 2050 from 43.1 million in 2012.
Europe is also estimated to hold considerable market share during the forecast period owing to the increasing disposable income coupled with presence of highly innovative healthcare infrastructure and manufacturers. This is likely to assist the market growth for facial injectable over the forecast period. Furthermore, local presence of major players including ALLERGAN, Sinclair Pharma, Ipsen, and Galderma S.A. are likely to assist in growth of this vertical.Competitor overview
Some of the key players include ALLERGAN; Merz Pharma; Suneva, Ipsen; Medical, Inc.; Prollenium Medical Technologies Inc.; Medytox, Inc.; Bloomage BioTechnology Corporation Limited; Sinclair Pharma; Anika Therautics, Inc.; and Galderma S.A. The players focusing on growth strategies, such as partnerships, new product launches, regional expansions mergers and acquisitions. For instance, in Jan 2017, ALLERGAN introduced Juvéderm Volite, a hyaluronic acid based injectable gel used to smoothen the face lines, décolletage, neck, and hands in adults.Key Players
- Merz Pharma;
- Suneva Medical, Inc.;
- Medytox, Inc.;
- Sinclair Pharma;
- Bloomage BioTechnology Corporation Limited;
- Anika Therapeutics, Inc.;
- Prollenium Medical Technologies Inc.;
- Galderma S.A.
- Hyaluronic Acid
- Botulinum Toxin Type A
- Calcium Hydroxylapatite
- Polymer Fillers
- North America
- Rest of Europe
- South Korea
- Rest of Asia-Pacific
- Saudi Arabia
- Rest of LAMEA